Latest Report Of Egypt Cardiovascular Diseases Drug Market Growth, Opportunities, Risk, Challenges, Gross Margin, Covid-19 Outbreaks

Egypts Cardiovascular diseases drugs market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

In Egypt, cardiovascular disease (CVD) has been the leading cause of premature death since the 1990s. It is the most populous of the Middle East and North American countries and recent studies revealed higher CAD mortality rates in this region. In 2017, CVD accounted for 46.2% of the overall mortality in Egypt. Given the aging of the population and the success in prolonging the survival of those with coronary events, heart failure (HF) poses an important and growing public health burden.

Recent studies expressed that ACS patients in Egypt are relatively young (mean age 57 years) compared with patients living in the West (mean age 66 years). In line with the Cardio Risk study done across Egypt, central obesity, diabetes, and hypertension were more prevalent in women with ACS and were acknowledged as major risk factors for ACS. With these statistics, the market for the disease is likely to grow in demand in the forecast period.

Market Drivers

Egypt's epidemiological profile, characterized by a high chronic disease burden, will drive prescription medicine expenditure over the coming years. Rapid population growth and a gradually aging population represent potential for pharmaceutical firms to expand, with the emergence of diabetes, hypertension, and cardiovascular diseases driving the growth of higher value prescription medicines.

The disease burden of Cardiovascular has consistently topped the list of most death-causing diseases in Egypt and is likely to grow in the future. Ischemic heart disease has consistently remained on top of the table for Egypt and the deaths caused by it have seen a rise of 26.9% from 2009 to 2019. It is also the no. one cause for DALYs in Egypt. Mortality caused by Hypertensive heart diseases has seen a rise of 24.4.% from 2009 to 2019.

Further, data indicate that the elder population has a higher prevalence of CAD risk factors. Given that the geriatric population of Egypt is expected to expand by more than twice its present size, the risk of cardiovascular disease will also increase. Such a rise in the burden of the disease will drive the cardiovascular disease drug market in Egypt.

Other initiatives such as 100 million healthy Lives, launched in Egypt will drive the NCD pharmaceuticals market due to increased awareness, diagnosis, and treatment among the population.

This indicates that the pharmaceutical market of Egypt is likely to encourage local players more than international penetration in the near future.

Get Exclusive Free Sample Report @ https://www.prudentmarkets.com/sample-request/140087/

Major Players

Egypt's Cardiovascular diseases treatment market appears to be fragmented with the presence of several local and global companies including AstraZeneca, Novartis, GSK, Sanofi, Pharco, Amoun, EIPICO, Eva Pharma, Pfizer, Hikma, SEDICO.

AstraZeneca's production in Egypt was previously contracted out to a local manufacturer. AstraZeneca has since built a pharmaceuticals production facility near Cairo, which produces a broad range of the company's products including cardiovascular and cancer treatments. The decision by AstraZeneca to focus on three product lines in Egypt - cardiovascular, cancer and psychiatric drugs - follows local epidemiological trends

SEDICO's product portfolio includes analgesics, antihistamines and nasal decongestants, antidepressants and cardiovascular drugs. As such, the company is well placed to continue taking advantage of the country's disease profile and its growing population. SEDICO manufactures its own products and those under licence from various multinationals, including AstraZeneca UK, as well as other foreign players, such as Trenka (based in Austria).

 

The report delivers the challenges in front of the Egypt Cardiovascular Diseases Drug Market 2023 that allows a better understanding of the market providing a helpful comprehensive evaluation and clear-cut dynamics associated with this market. The analyst has studied the current market scenario while concentrating on the new business objectives with the lucrative opportunities that are available. This report includes changes in customer requirements, customer preferences, and the vendor landscape in the industry with key factors that are expected to influence the overall dynamics of the Egypt Cardiovascular Diseases Drugs Market including the current trends, growth opportunities, restraints, and market drivers.

To Know More About COVID-19 Impact On Egypt Cardiovascular Diseases Drug Market @ https://www.prudentmarkets.com/sample-request/140087/

By Drug class

The market for the treatment of cardiovascular disease has been segmented on types of drugs available for the diseases mainly Antihypertensive, Antihyperlipidemic, Anticoagulants, and antiplatelet drugs

By Disease Indication

On the basis of disease indication, the cardiovascular drugs market is segmented into Hypertension, Hyperlipidaemia, Coronary Artery Disease, and Arrhythmia

By Distribution Channel

By distribution channel, the market for cardiovascular drugs in Egypt can be segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

Major Players

Egypt's Cardiovascular diseases treatment market appears to be fragmented with the presence of several local and global companies including AstraZeneca, Novartis, GSK, Sanofi, Pharco, Amoun, EIPICO, Eva Pharma, Pfizer, Hikma, SEDICO.

AstraZeneca's production in Egypt was previously contracted out to a local manufacturer. AstraZeneca has since built a pharmaceuticals production facility near Cairo, which produces a broad range of the company's products including cardiovascular and cancer treatments. The decision by AstraZeneca to focus on three product lines in Egypt - cardiovascular, cancer and psychiatric drugs - follows local epidemiological trends

SEDICO's product portfolio includes analgesics, antihistamines and nasal decongestants, antidepressants and cardiovascular drugs. As such, the company is well placed to continue taking advantage of the country's disease profile and its growing population. SEDICO manufactures its own products and those under licence from various multinationals, including AstraZeneca UK, as well as other foreign players, such as Trenka (based in Austria).

 

The Egypt Cardiovascular Diseases Drug Market report is an easy-to-understand document giving section-wise details about the global market. Starting with the brief outline of the overall market, it will put forth the all-inclusive evaluated market statistics and different parameters for the forecast period. The report covers numerous aspects of the Egypt Cardiovascular Diseases Drug market divided into product kind, application, and end-use, offering the report to assist the customers in improving their ability to make precise decisions related to the business under the Egypt Cardiovascular Diseases Drug Market.

International Market Players will use the correct market facts and figures and applied math studies provided within the report back to perceive this and future growth of the worldwide Electrophoretic Egypt Cardiovascular Diseases Drug market. Each section of the research study is specially prepared to explore key aspects of the global Egypt Cardiovascular Diseases Drug Market. Buyers of the report will have access to accurate PESTLE, SWOT, and other types of analysis on the global Egypt Cardiovascular Diseases Drug market. Moreover, it offers highly accurate estimations on the CAGR, market share, and market size of key regions and countries.

This post-pandemic business planning research will aid clients to:
• Adjust their strategic planning to move ahead once business stability kicks in.
• Build resilience by making effective resource and investment choices for individual business units, products, and service lines.
• Conceptualize scenario-based planning to mitigate future crisis situations.

Instant Buy This Report and Get Up To 40% Discount [Use Corporate Email ID]: https://www.prudentmarkets.com/discount-request/140087/

Get full copy of 225+ pages research report (Inclusion of updated research on COVID-19) on United States Region at $1500 and, Europe region at $2000. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Our qualified team of researchers, analysts, and consultants use in-depth qualitative research, quantitative research, and the latest recognized research techniques to offer an unrivaled level of detail and value to your research activities. Our market and competitive intelligence can be utilized by teams across multiple departments, including sales and business development, marketing, to:

• Access the latest information on potential competitors and customers through a comprehensive database
• Analyse the business strategies and collaborations of multiple companies within a specific market
• Identify new markets and regions for future expansion
• Compare financial trends between competitor companies
• Get to know about mergers and acquisitions
• Explore the strengths and weaknesses of companies cross-industry
• Improve your business modeling

Strategic Points Covered in Table of Content of Global Egypt Cardiovascular Diseases Drug Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Egypt Cardiovascular Diseases Drug market
Chapter 2: Exclusive Summary - the basic information of the Egypt Cardiovascular Diseases Drug Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the Egypt Cardiovascular Diseases Drug
Chapter 4: Presenting the Egypt Cardiovascular Diseases Drug Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the Egypt Cardiovascular Diseases Drug market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

(If you have any special requirements, please let us know and we will offer you the report as you want.)

Inquire Before Purchasing The Complete Report To Grow Your Business: https://www.prudentmarkets.com/enquiry-request/140087/

Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: sales@prudentmarkets.com
Web: www.prudentmarkets.com

About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.

This release was published on openPR.